X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MYMD-1 (isomyosamine), a next generation, oral selective inhibitor of tumor necrosis factor-alpha, a driver of chronic inflammation, being studied for rheumatoid arthritis.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
MYMD-1, a next generation, oral selective inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of chronic inflammation, is being studied to slow the aging process, prevent sarcopenia and frailty, and extend healthy lifespan.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. It is being investigated as therapy for delaying aging.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier. It is being investigated for rheumatoid arthritis.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
The financing will support the continued development of MYMD-1 for sarcopenia, an aging indication. MYMD-1® regulates the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17A.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 21, 2023
Details:
MYMD-1 is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based diseases are treated due to its selectivity and ability to cross the blood brain barrier.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
MYMD-1 (isomyosamine) is an oral next-generation TNF-α inhibitor with the potential to transform the way that TNF-α based autoimmune diseases are treated.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
MYMD-1 (isomyosamine) with its ability to cross the blood brain barrier, has the promise to provide meaningful therapeutic solutions to patients not served by current TNF-alpha inhibitors and as a potential therapy for CNS-based inflammatory and autoimmune diseases.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
MYMD-1’s ease of oral dosing is another differentiator compared to currently available TNF-α blockers, all of which require delivery by injection or infusion. MYMD-1 (isomyosamine), has shown effectiveness in pre-clinical and clinical studies in regulating the immune system.
Lead Product(s): Isomyosamine
Therapeutic Area: Ophthalmology Product Name: MYMD-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bascom Palmer Eye Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 12, 2022
Details:
The data demonstrated a statistically significant decrease in TNF-α levels (p-value <0.05) found in MYMD-1 (isomyosamine) treated subjects, but no change in the participants given placebo.
Lead Product(s): Isomyosamine
Therapeutic Area: Musculoskeletal Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Primary endpoint for Phase 2 clinical trial for MYMD-1, oral immune regulator, achieve reduction in circulating levels of TNF-α, TNFRI and IL-6 also and demonstrated significant efficacy in reducing levels of TNF-α, a key in causing pathological aging in Phase 1 trial.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Details:
MYMD-1 believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging has shown effectiveness in pre-clinical studies.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression.
Lead Product(s): Isomyosamine
Therapeutic Area: Psychiatry/Psychology Product Name: MYMD-1
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
Details:
In addition to JAK inhibition, MYMD-1 has shown efficacy as a selective inhibitor of TNF-α, a driver of chronic inflammation. MYMD-1 has also been shown to be effective in traversing the blood-brain barrier, a differentiator that can increase the drug’s benefit to patients.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
Following the merger, the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets, including MYMD-1, a novel drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: MyMD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
